IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice.
To facilitate the establishment of mixed chimerism with limited dose of bone marrow (BM) cells, and to achieve tolerance in skin graft model, combined blocking of costimulatory pathway and IL-2 pathway was used in minimally myeloablative model using busulfan. BM cells (2.5x10(7)) of BALB/c were injected into C57BL/6 mice at day 0 with full thickness skin graft after single dose injection of busulfan (25 mg/kg) on day-1. Recipients were grouped and injected the anti-CD154, CTLA4-Ig, anti-IL-2R at days 0, 2, 4, and 6 according to protocol. Mixed macrochimerism were induced in groups treated with anti-CD154+anti-CTLA4-Ig, anti-CD154+anti-IL-2R, and anti-CD154+anti-CTLA4 Ig+anti-IL-2R. Three groups having chimerism enjoyed prolonged graft survival more than 6 months. Superantigen deletion study revealed deletion of alloreactive T cells in combined blockade treated groups. In graft versus host disease model using CFSE staining, CD4+ T cell and CD8+ T cell proliferation were reduced in groups treated with CTLA4-Ig or anti-IL-2R or both in combination with anti-CD154. However, anti-IL-2R was not so strong as CTLA4-Ig in terms of inhibition of T cell proliferation. In conclusion, IL-2 pathway blocking combined with anti-CD154 can establish macrochimerism with limited dose of BM transplantation and induce specific tolerance to allograft.
Lee
Jeong-hoon
JH
Department of Surgery, Hallym University College of Medicine, Chuncheon, Korea.
Ha
Jongwon
J
Kim
Shi-hwa
SH
Kim
Sang Joon
SJ
D000069594:Abatacept; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage* / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000379:methods; D023201:CD40 Ligand / Q000276:immunology*; D004338:Drug Combinations; D006085:Graft Survival / Q000276:immunology*; D018796:Immunoconjugates / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016038:Skin Transplantation / Q000276:immunology* / Q000379:methods
D000906:Antibodies; D004338:Drug Combinations; D018796:Immunoconjugates; D007376:Interleukin-2; D023201:CD40 Ligand; D000069594:Abatacept